# Moberg Pharma > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/mobergpharma). ## Overview Moberg Pharma AB is a Swedish pharmaceutical company focused on the development and commercialization of medical products, particularly in the area of dermatology. The company is known for its innovative treatments for nail fungus, with its flagship product MOB-015 receiving approval in multiple European countries. Moberg Pharma operates primarily through strategic partnerships, allowing it to leverage local expertise for marketing and distribution while focusing its resources on research and development. The company aims to expand its market presence in Europe and eventually enter the U.S. market pending further clinical studies and FDA approval. ## Products & services • MOB-015 antifungal treatment • Terclara® brand products • Licensing agreements for product distribution • Research and development services • Manufacturing and product supply - **Antifungal Treatments** (70%) — Includes MOB-015 and related products for nail fungus treatment - **Licensing Agreements** (20%) — Revenue from partnerships for product distribution - **Research and Development** (10%) — R&D services for pharmaceutical development - MOB-015 antifungal treatment - Terclara® brand products - Licensing agreements for product distribution - Research and development services - Manufacturing and product supply ## Customers Moberg Pharma primarily serves pharmaceutical companies and healthcare providers through its strategic partnerships. These partners are responsible for marketing and selling Moberg's products in their respective regions, such as Europe, Canada, and Israel. The company's products are targeted at adults suffering from mild to moderate fungal infections, with a focus on providing effective and convenient treatment options. Moberg Pharma's business model allows it to maintain a lean operational structure while leveraging the marketing and distribution capabilities of its partners. - **Pharmaceutical Partners** (primary) — Partners who market and distribute MOB-015 in specific regions - **Healthcare Providers** (secondary) — Providers offering MOB-015 to patients with nail fungus - **End Consumers** (emerging) — Adults using MOB-015 for nail fungus treatment - Pharmaceutical companies seeking effective antifungal treatments - Healthcare providers looking for innovative dermatology solutions - Partners in Europe, Canada, and Israel for regional distribution - Adults with mild to moderate fungal infections of the nails ## Geography Moberg Pharma is headquartered in Sweden and has a significant presence in Europe through its partnerships. The company has secured national approvals for its products in 13 European countries and is actively expanding its market presence. In addition to Europe, Moberg Pharma has partnerships in Canada and Israel, enabling a broader geographic reach. The company's long-term strategy includes entering the U.S. market, which is the largest market for onychomycosis treatments globally. - Headquartered in Sweden with a focus on European markets - National approvals in 13 European countries for MOB-015 - Partnerships in Canada and Israel for product distribution - Long-term goal to enter the U.S. market ## Strategy Moberg Pharma's strategic priorities include expanding its market presence in Europe and preparing for a future U.S. launch. The company leverages strategic partnerships to distribute its products, allowing it to focus on R&D and product development. Moberg Pharma aims to enhance its product portfolio through acquisitions and partnerships, positioning Terclara as a premium brand. The company is also focused on generating additional clinical data to support FDA approval for its products in the U.S. - **European Market Expansion** (medium-term) — To establish a strong market presence and drive revenue growth - **U.S. Market Entry** (long-term) — To access the largest market for onychomycosis treatments - Expand market presence in Europe with approved products - Prepare for U.S. market entry with additional clinical studies - Leverage partnerships for product distribution - Enhance product portfolio through acquisitions ## Risks Moberg Pharma faces several risks typical of the pharmaceutical industry, including regulatory challenges, market risks, and the need for continuous innovation. The company's success depends on the outcomes of clinical trials and obtaining necessary regulatory approvals. Financial risks include the need for substantial capital investment and sensitivity to economic fluctuations. Additionally, the company relies on key partnerships for distribution, which poses a risk if these partnerships are disrupted. - **Regulatory Approval Delays** [high] — Could delay market entry and revenue generation - **Clinical Trial Outcomes** [critical] — Negative results could impact product development - **Partnership Disruptions** [high] — Could affect distribution and sales - Regulatory challenges in obtaining product approvals - Market risks associated with product launches and competition - Dependence on successful clinical trial outcomes - Financial risks due to high capital requirements - Reliance on key distribution partnerships ## Accounting Moberg Pharma's financial statements are prepared in accordance with IFRS, with a focus on the capitalization of development expenses for MOB-015. The company has not yet begun amortization of these expenses, which could impact future financial results. Revenue recognition is based on milestone payments and royalties from partnerships, which may lead to fluctuations in reported revenue. The company also faces potential impairment of intangible assets if product development does not progress as expected. - **Development Expense Capitalization** — high - **Revenue Recognition** — medium - Capitalization of development expenses for MOB-015 - Revenue recognition based on milestone payments and royalties - Potential impairment of intangible assets - Fluctuations in revenue due to partnership agreements --- *Last updated: 2026-08-11T04:04:54.268470+00:00*